Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
Both organisations enter into a long- term collaboration to expand patient access in India
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The company is confident of addressing the concern raised by the USFDA
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated